Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

Hylton V Joffe1, Ruliang Xu, F Bradley Johnson

  • 1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Thrombosis and Haemostasis
|June 4, 2004
PubMed
Summary

Genetic variations in CYP2C9, specifically CYP2C9*2 and *3, significantly impact warfarin metabolism. These genetic factors are key predictors of very low warfarin dose needs and influence anticoagulation control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of micro dual temperature-heat flux sensing probe using Pt Thin film for transient heat measurements up to 1400 °C.

Microsystems & nanoengineering·2026
Same author

Clinical and patient-reported outcomes after drug-coated balloon angioplasty for femoropopliteal peripheral artery disease.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.

The New England journal of medicine·2026
Same author

Post-pulmonary embolism cardiac impairment and chronic thromboembolic pulmonary hypertension after ultrasound-assisted catheter-directed thrombolysis for acute pulmonary embolism.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.

The New England journal of medicine·2026
Same author

Endovascular treatment of acute upper extremity deep vein thrombosis in Paget-Schroetter syndrome: A longitudinal analysis of three endovascular techniques.

Journal of vascular surgery. Venous and lymphatic disorders·2026

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology

Background:

  • Warfarin dosing is complex, influenced by genetic and non-genetic factors.
  • Cytochrome P450 2C9 (CYP2C9) is crucial for warfarin metabolism.
  • CYP2C9*2 and *3 genetic variants are associated with impaired warfarin metabolism.

Purpose of the Study:

  • To determine if CYP2C9*2 and *3 polymorphisms explain low warfarin dose requirements.
  • To assess the association between these polymorphisms and hemorrhagic complications.
  • To evaluate warfarin dosing and outcomes after excluding non-genetic factors.

Main Methods:

  • Retrospective observational study of 73 patients at an Anticoagulation Clinic.
  • Patients categorized into low (≤2 mg), moderate (4-6 mg), and high (≥10 mg) daily warfarin dose groups.

Related Experiment Videos

  • CYP2C9 genotyping performed using PCR and restriction enzyme digestion.

    • Main Results:

    • CYP2C9 polymorphisms independently predicted low warfarin requirements (OR 24.80).
    • Variant alleles were present in 88% of the low-dose group, 37% of moderate, and 7% of high-dose groups.
    • Homozygotes/compound-heterozygotes for variant alleles required ≤1.5 mg daily warfarin.

    Conclusions:

    • CYP2C9*2 or *3 variants are strong predictors of low warfarin requirements, independent of other factors.
    • These polymorphisms increase excessive anticoagulation risk but not necessarily bleeding when monitored.
    • Genetic testing for CYP2C9 variants can aid in personalized warfarin therapy.